Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019

    NEXT STORY
    CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook
    PREV STORY
    Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments

    author_avatar
    NASDAQ Market News

    Pulmonary Arterial Hypertension Treatment Market to Attain a Value of US$ 6.5 Billion by 2028– Future Market Insights

    Combination Therapeutics & Innovations to Sustain Pulmonary Arterial Hypertension Treatment MarketVALLEY COTTAGE, N.Y. , ...

    author_avatar
    NASDAQ Market News

    RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®

    RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, ...

    author_avatar
    NASDAQ Market News